Brexit: Life Science Firms In An ‘Impossible Position’
Guidance Still Awaited On Licensing & Pharmacovigilance
Executive Summary
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
You may also be interested in...
Industry Gets Breathing Space For Post-Brexit Regulation In Northern Ireland
The pharmaceutical industry has welcomed a decision to allow more time to bring in new medicines regulations in Northern Ireland, but continues to insist that a mutual recognition agreement between the UK and the EU on drug manufacturing is the best way forward.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.